Oppenheimer raises Palvella Therapeutics price target to $232 from $210
Oppenheimer has lifted its price target on Palvella Therapeutics shares to $232 a share from $210, according to Dow Jones Newswires.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to Dow Jones Newswires, Oppenheimer raised its price target on Palvella Therapeutics (PVLA) shares to $232 per share from $210. The information is based on rating actions compiled by Benzinga, which also links to a page with analyst ratings for the company.
why it matters
A price target change reflects one analyst's view of what the shares are worth, not a new development in the company's business. Such decisions are mainly of interest to investors in the stock and have little effect on the broader market.
tags
instruments
sources
- Palvella Therapeutics Price Target Raised to $232.00/Share From $210.00 by Oppenheimer — Dow Jones Newswires, 6 November 2026 at 17:34 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗